About Prof. Chen Tong
Prof. Chen Tong (陈彤) is the Director of the Department of Hematology at Huashan Hospital, Fudan University — one of Shanghai's most prestigious academic medical centers. A comprehensive hematologist with deep expertise across all major hematological malignancies, Prof. Chen is particularly recognized for his pioneering work in exploring novel lymphoma therapies and his research into the hematopoietic microenvironment — the complex ecosystem of cells and signals within the bone marrow that governs blood cell production and plays a critical role in the development and treatment resistance of blood cancers.
Prof. Chen's dual identity as a clinician and researcher gives his patients access to the latest investigational therapies and a treatment philosophy grounded in the most current understanding of lymphoma biology. His department at Huashan Hospital serves as a referral center for complex hematological cases across Shanghai and eastern China, with a particular strength in patients who have failed standard therapies and require innovative approaches.
Clinical Expertise
- Lymphoma — novel therapy exploration: clinical investigation and application of emerging agents including bispecific antibodies, next-generation BTK inhibitors, antibody-drug conjugates (ADCs), and novel immunotherapy combinations for relapsed and refractory lymphoma
- Hematopoietic microenvironment research: deep expertise in how the bone marrow niche influences lymphoma development, treatment resistance, and response to cellular therapies — with direct implications for patient management
- Comprehensive hematological malignancies: lymphoma (all subtypes), leukemia (AML, ALL, CLL), multiple myeloma, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
- CAR-T cell therapy: patient selection, pre-treatment optimization, and management of CAR-T-related toxicities (CRS, ICANS) for eligible patients with relapsed/refractory B-cell lymphoma and other hematological malignancies
- Hematopoietic stem cell transplantation (HSCT): autologous and allogeneic transplant coordination for eligible patients as consolidation or salvage therapy
- Clinical trials: access to investigational novel agents through Huashan Hospital's active hematology research program
Why Prof. Chen Tong?
Prof. Chen's expertise in the hematopoietic microenvironment represents a frontier of lymphoma research with direct clinical relevance. The bone marrow niche — the cellular and molecular environment surrounding blood-forming cells — is increasingly understood to play a critical role in how lymphoma cells evade treatment, develop resistance to chemotherapy and targeted agents, and respond (or fail to respond) to CAR-T cell therapy. Prof. Chen's research in this area informs his clinical decision-making in ways that go beyond standard protocol application.
For patients with relapsed or refractory lymphoma who have exhausted standard options, Prof. Chen's active involvement in novel therapy exploration means access to investigational agents and combination strategies that may not yet be widely available. His position as department director at Huashan — a hospital with strong research infrastructure and a history of clinical innovation — provides the institutional support needed to pursue these approaches safely and effectively.
Huashan Hospital's hematology department also offers a complementary perspective to FUSCC's lymphoma program: while FUSCC is China's premier dedicated cancer center, Huashan's strength in comprehensive hematology — spanning lymphoma, leukemia, myeloma, and transplant — makes it particularly well-suited for patients with complex or overlapping hematological conditions, or those requiring integrated transplant and cellular therapy planning.
Hospital: Huashan Hospital, Fudan University
Huashan Hospital is one of China's most prestigious academic medical centers, affiliated with Fudan University School of Medicine and consistently ranked among the top hospitals in the country. Its Department of Hematology is a comprehensive center for blood cancer diagnosis and treatment, with capabilities spanning advanced molecular diagnostics, CAR-T cell therapy, hematopoietic stem cell transplantation, and an active clinical trials program. The hospital's strong research culture and multidisciplinary infrastructure make it a leading destination for patients with complex hematological malignancies.
About Lymphoma & Novel Therapies
The lymphoma treatment landscape has transformed dramatically in recent years, with a wave of novel agents offering new options for patients who have failed standard chemotherapy. Key advances that Prof. Chen's team works with:
- Bispecific antibodies (glofitamab, mosunetuzumab, epcoritamab): engage both T-cells and lymphoma cells simultaneously, producing response rates of 35–60% in heavily pre-treated DLBCL without the need for apheresis or manufacturing delays associated with CAR-T
- Next-generation BTK inhibitors (zanubrutinib, acalabrutinib): superior selectivity and tolerability vs. first-generation ibrutinib; approved for MCL, CLL, and Waldenström macroglobulinemia with expanding indications
- Antibody-drug conjugates (ADCs): polatuzumab vedotin (anti-CD79b), loncastuximab tesirine (anti-CD19), and camidanlumab tesirine (anti-CD25 for Hodgkin) deliver cytotoxic payloads directly to lymphoma cells
- CAR-T cell therapy: multiple products approved in China; response rates of 50–70% in relapsed/refractory DLBCL; increasingly used earlier in the treatment sequence
- Hematopoietic stem cell transplantation: autologous HSCT remains standard consolidation for eligible patients achieving second remission; allogeneic HSCT offers potential cure for selected high-risk cases
- Hematopoietic microenvironment targeting: emerging strategies that disrupt the protective niche lymphoma cells exploit to evade therapy — an area where Prof. Chen's research expertise is directly applicable
What to Prepare Before Your Consultation
To enable Prof. Chen's team to conduct a thorough remote case review, international patients should prepare:
- Pathology report with full IHC panel and molecular subtyping (cell-of-origin, MYC/BCL2/BCL6 FISH, NGS if available)
- PET-CT scan for staging and response assessment
- Bone marrow biopsy report if performed
- LDH, beta-2 microglobulin, CBC with differential, and comprehensive metabolic panel
- Complete treatment history: all prior regimens, cycle numbers, dates, and best response
- Prior CAR-T or stem cell transplant records if applicable
- Current performance status and any active symptoms or complications
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Prof. Chen Tong and the Huashan Hospital hematology team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Prof. Chen's team at Huashan Hospital
- Full translation of pathology reports, imaging, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comments